MSB 3.21% $1.13 mesoblast limited

Ann: 83% Survival in COVID-19 ARDS Patients with Remestemcel-L, page-799

  1. 2,095 Posts.
    lightbulb Created with Sketch. 85
    Just wondering if you have any details of the Expanding clinical trial Mesoblast is recruiting right now! Interesting to read up on the description and design for the groups!
 
watchlist Created with Sketch. Add MSB (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.